(MONROVIA, CA): Pace Diagnostics, an emerging California-based biotech start-up, has initiated a crowd-funding campaign for help to launch a novel and sensitive COVID-19 Antigen Rapid Detection Home Test that will boost the accessibility of COVID-19 testing worldwide.
A second corona virus wave is sweeping continental Europe, with new infection records broken daily in many countries. With cases spiking across the continent, many European countries are re-imposing restrictions, including travel warnings, mask mandates and partial lockdowns, in hopes of curbing corona virus outbreaks that are leading to increased hospitalizations and deaths. Many countries are turning to rapid antigen tests to contain the second wave, including the US and Canada.
Additionally, the effective duration of the vaccines is unknown. It is imperative that the general public should have access to inexpensive, simple, and accurate HOME tests. And this is exactly what Pace Diagnostics has come up with; an affordable truly HOME test with worldwide accessibility, no appointments, no waiting, fully privacy with results within 15 minutes.
After successfully developing rapid tests for early detection of lung cancer and tuberculosis, which have advanced to pre-clinical trial stage, Pace Diagnostics is ready to take on the challenge of providing COVID-19 HOME Antigen Rapid Detection Test (RDT) and help to bring the pandemic under control. According to the company spokesperson, “Our COVID-19 Antigen RDT will provide results within 15 minutes and can detect an ongoing infection, allowing users to make appropriate healthcare and lifestyle decisions.”
The campaign will be running for several weeks, with donations used to cover manufacturing, clinical testing, regulatory submission, and deployment once the Company gets the green light. The demand for these COVID-19 Antigen Rapid Detection Tests has been estimated to be ~500 million in 2020-2021.
“We need more accurate and quicker diagnostics test kits; kits that are simple to use, affordable and accurate enough for quick screening purposes,” the President of Pace Diagnostics, Dr. Nguyen commented. “Especially during this COVID-19 pandemic, the need for inexpensive, convenient, and easy-to-use tests capable of providing visually accurate FAST results is now more than ever.”
Despite hundreds of millions of dollars spent by the U.S. government and large investors to deploy Antigen Rapid Detection Tests, not much funding has been made available to highly innovative players like Pace Diagnostics, whose predecessor received several Small Business Innovation Research grants in the last decade. The company is turning to the public and the power of community funding for help to launch this test.
More information is available at https://www.pacediagnostics.com/